ATP-binding cassette transporters in inflammatory brain disease

Pharmacology, Toxicology and Pharmaceutical Science

• Brain Disease 100%
• ABC Transporter 100%
• HIV 50%
• Adverse Event 50%
• Inflammation 50%
• Neurologic Disease 50%
• Central Nervous System Disease 50%
• Pharmacogenetics 50%
• Antiviral Drug 50%
• Multiple Sclerosis 50%
• Therapeutic Window 50%
• Mitoxantrone 50%
• Experimental Autoimmune Encephalomyelitis 50%
• Anthraquinone 50%
• Encephalitis 50%
• HIV Associated Dementia 50%
• Drug Fatality 50%
• Cytostatic 50%

Neuroscience

• ABC Transporter 100%
• Brain Disease 100%
• Multiple Sclerosis 50%
• Human Immunodeficiency Virus 50%
• Encephalitis 50%
• Nervous System Disorder 50%
• Genetic Variation 50%
• Experimental Autoimmune Encephalomyelitis 50%
• HIV Associated Dementia 50%
• Mitoxantrone 50%
• Anthraquinone 50%
• Side Effect 50%

Keyphrases

• ATP-binding Cassette Transporter A1 (ABCA1) 100%
• Inflammatory Brain Disease 100%
• Treatment Response 28%
• Genetic Variation 14%
• Adverse Events 14%
• Autoimmune 14%
• Therapeutic Agents 14%
• Treatment Strategy 14%
• Multiple Sclerosis 14%
• Neurovascular Unit 14%
• Neurodegenerative 14%
• Individualized Treatment 14%
• Cytostatic 14%
• Neurological Diseases 14%
• Antiviral Agents 14%
• HIV-associated Neurocognitive Disorders 14%
• Inflammatory Conditions 14%
• Predictive Role 14%
• Mitoxantrone 14%
• Anti-neuroinflammation 14%
• Experimental Autoimmune Encephalomyelitis 14%
• Anthracenedione 14%
• Response Event 14%
• Pharmacogenetic Study 14%
• CNS Penetration 14%
• Narrow Therapeutic Index 14%
• Model Experimental 14%
• HIV Encephalitis 14%
• Therapeutic Progress 14%
• Inflammatory CNS Disease 14%